Synergistic activity of azithromycin and pyrimethamine or sulfadiazine in acute experimental toxoplasmosis - sprookjes - yvandenbroek - TriplyDB

Synergistic activity of azithromycin and pyrimethamine or sulfadiazine in acute experimental toxoplasmosis

Synergistic activity of azithromycin and pyrimethamine or sulfadiazine in acute experimental toxoplasmosis

http://www.wikidata.org/entity/Q28326714

about

sameAs

In vitro evaluation of the activities of azithromycin alone and combined with pyrimethamine against Toxoplasma gondii Ciprofloxacin Derivatives Affect Parasite Cell Division and Increase the Survival of Mice Infected with Toxoplasma gondii Localization of azithromycin in Toxoplasma gondii-infected cells Evaluation of a cyclic GMP-dependent protein kinase inhibitor in treatment of murine toxoplasmosis: gamma interferon is required for efficacy.Sulfadiazine and pyrimethamine in the postnatal treatment of congenital toxoplasmosis: what are the options?The Impact of Short-Term, Intensive Antifolate Treatment (with Pyrimethamine and Sulfadoxine) and Antibiotics Followed by Long-Term, Secondary Antifolate Prophylaxis on the Rate of Toxoplasmic Retinochoroiditis Recurrence.Azithromycin versus Sulfadiazine and Pyrimethamine for non-vision-threatening toxoplasmic retinochoroiditis: a pilot study.Synergistic activity of clarithromycin and minocycline in an animal model of acute experimental toxoplasmosis Antiparasitic treatment suppresses production and avidity of Toxoplasma gondii-specific antibodies in a murine model of acute infection*.In vitro and in vivo activities of the hydroxynaphthoquinone atovaquone alone or combined with pyrimethamine, sulfadiazine, clarithromycin, or minocycline against Toxoplasma gondii.Therapeutic approaches for AIDS-related toxoplasmosis.Preparation of (131)I-Pyrimethamine and evaluation for scintigraphy of experimentally Toxoplasma gondii-infected rats.[Evaluation of the efficacy of azithromycin and pyrimethamine, for treatment of experimental infection of mice with Toxoplasma gondii cystogenic strain].Evaluation of Current and Emerging Antimalarial Medicines for Inhibition of Toxoplasma gondii Growth in Vitro

P2860

Q28378355-5D38E678-2219-4058-9F55-A2AA79B3844F Q28547065-8D95B551-E269-4A51-BBCC-0751E9ED08D8 Q33755229-4AD86E83-F183-4C1D-B184-9FA3F345305D Q34105538-8DDA3FE5-9075-4863-896E-D01B9693AE23 Q35917170-DA043E62-9387-412C-AB6F-9CFA4094103B Q36107947-8C06F4A2-6AFB-4025-ADA2-5CB0F338B4AD Q36577019-3CF7730E-6414-42EA-BBAD-5B126DE73521 Q36758482-709DC7F4-C91D-4AA7-89D9-685E9B168871 Q37531268-BE99E125-3EA3-463A-8A95-2ADBBA4FD50D Q39882492-25EB2D18-CB74-4CB8-B034-67F2D8EB85AC Q40921769-368B27C9-B505-4360-87E4-83814418EF9D Q44119074-5144E6E9-3555-4811-B9D2-1992F0B5A5CB Q46376378-8D886249-8132-4B66-953E-361DA9F8FA1B Q56344152-3F8E4CD6-9AF0-4217-9045-F605DC5C08D7

P2860

Synergistic activity of azithromycin and pyrimethamine or sulfadiazine in acute experimental toxoplasmosis

http://www.wikidata.org/entity/Q28326714

description

1992 nî lūn-bûn

@nan

1992 թուականի Մայիսին հրատարակուած գիտական յօդուած

@hyw

1992 թվականի մայիսին հրատարակված գիտական հոդված

@hy

1992年の論文

@ja

1992年論文

@yue

1992年論文

@zh-hant

1992年論文

@zh-hk

1992年論文

@zh-mo

1992年論文

@zh-tw

1992年论文

@wuu

name

Synergistic activity of azithr ...... ute experimental toxoplasmosis

@ast

Synergistic activity of azithr ...... ute experimental toxoplasmosis

@en

Synergistic activity of azithr ...... ute experimental toxoplasmosis

@nl

type

label

Synergistic activity of azithr ...... ute experimental toxoplasmosis

@ast

Synergistic activity of azithr ...... ute experimental toxoplasmosis

@en

Synergistic activity of azithr ...... ute experimental toxoplasmosis

@nl

prefLabel

Synergistic activity of azithr ...... ute experimental toxoplasmosis

@ast

Synergistic activity of azithr ...... ute experimental toxoplasmosis

@en

Synergistic activity of azithr ...... ute experimental toxoplasmosis

@nl

P1433

Q28326714-6F7643C3-8A70-4A7E-843A-FD04F8006933

P1476

Q28326714-7D5873EE-F88C-448B-A6D1-C8BAC1B8CC63

P2093

Q28326714-224F7DA5-6248-43C1-9872-CD5EF2AD6D3C

Q28326714-4E800C25-5DC7-4804-98E1-F1EAA6C40A17

Q28326714-65398E1C-3101-4409-8FCE-155673C0EA08

Q28326714-77C5F425-2FE9-4B11-9367-D86E1A720548

Q28326714-DF946895-A66D-4835-9B13-FEA0256B0AD2

P2860

Q28326714-2C26905E-094B-48D1-993B-6B127F241D75

Q28326714-2F7F8AE3-4688-4E3C-BF49-918F2AE73994

Q28326714-743AEA1C-DBC9-452A-BB8E-CB2DEF410588

Q28326714-88FF5633-C269-4EC9-9A86-76D17043354C

Q28326714-8C08128A-A6EB-40C6-AA1D-1002CFDBE221

Q28326714-AD42D9BF-C838-49E1-B907-F68DD3B4BAEB

Q28326714-AF6B4BFC-BED9-4E85-B3FB-8A35CFE6AFD4

Q28326714-CFB006D6-F792-4FCD-9222-AB862C252F20

Q28326714-D568A839-1473-4070-A2CC-9ED7182380D9

Q28326714-F7AD453E-B86D-4846-8CEC-7E59B63D7F37

P304

Q28326714-17F87361-6306-46C2-B8D0-71EB5C4B908B

P31

Q28326714-F755285D-7E29-41DF-A8D7-E6C069905EC1

P3181

Q28326714-A3FAC4CF-2CA3-4D02-8211-38D6485A8838

P356

Q28326714-2F6C2F52-E59F-4F65-AC0A-DA8C05F8F4B9

P407

Q28326714-44F15E5F-5E59-49F1-A87B-0FD21FECBF4F

P433

Q28326714-031C4C7B-CBC3-4785-AEB4-05F2D69FFACD

P478

Q28326714-E0FE5334-A445-49FF-A592-137DBBCFEB1E

P577

Q28326714-AAC8151C-17C0-4995-8889-08FE2A920068

P5875

Q28326714-E0F74A20-EE93-4BAE-8749-E64566071C39

P698

Q28326714-4528B1C8-B1C6-41A2-97DB-FAE0833A44DB

P921

Q28326714-4F4FCFB4-2E1E-4B14-A3E5-BA41493AB038

Q28326714-561CF65B-8A80-4E2D-B1FD-5A441B6C47DB

Q28326714-7E0B05D2-8350-4782-99C1-C41C20DD50E3

P932

Q28326714-511C6396-EEB8-463A-B534-841C36BA5B31

P3181

P356

P1433

Antimicrobial Agents and Chemotherapy

P1476

Synergistic activity of azithr ...... ute experimental toxoplasmosis

@en

P2093

B Rouveix

http://www.w3.org/2001/XMLSchema#string

F Chau

http://www.w3.org/2001/XMLSchema#string

F Derouin

http://www.w3.org/2001/XMLSchema#string

J J Pocidalo

http://www.w3.org/2001/XMLSchema#string

R Almadany

http://www.w3.org/2001/XMLSchema#string

P2860

Evaluation of the effect of drugs on the cyst form of Toxoplasma gondii

In vivo activity of the macrolide antibiotics azithromycin, roxithromycin and spiramycin against Toxoplasma gondii

In vivo assessment of antimicrobial agents against Toxoplasma gondii by quantification of parasites in the blood, lungs, and brain of infected mice

In vitro effects of four macrolides (roxithromycin, spiramycin, azithromycin [CP-62,993], and A-56268) on Toxoplasma gondii

Azithromycin, a macrolide antibiotic with potent activity against Toxoplasma gondii

Pharmacokinetic and in vivo studies with azithromycin (CP-62,993), a new macrolide with an extended half-life and excellent tissue distribution.

Comparative activity of macrolides against Toxoplasma gondii demonstrating utility of an in vitro microassay.

New directions for macrolide antibiotics: pharmacokinetics and clinical efficacy.

In vitro and in vivo uptake of azithromycin (CP-62,993) by phagocytic cells: possible mechanism of delivery and release at sites of infection.

[In vitro measurement of the inhibitory effect of macrolides, lincosamides and synergestines on the growth of Toxoplasma gondii]

P304

997-1001

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P3181

3982716

http://www.w3.org/2001/XMLSchema#string

P356

10.1128/AAC.36.5.997

http://www.w3.org/2001/XMLSchema#string

P407

P433

5

http://www.w3.org/2001/XMLSchema#string

P478

36

http://www.w3.org/2001/XMLSchema#string

P577

1992-05-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

21830351

http://www.w3.org/2001/XMLSchema#string

P698

1324642

http://www.w3.org/2001/XMLSchema#string

P921

P932

188824

http://www.w3.org/2001/XMLSchema#string